The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model
- PMID: 18223695
- DOI: 10.1038/sj.bmt.1705996
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model
Abstract
Conditioning regimens are an important issue determining the outcome of hematopoietic stem cell transplantation (HSCT). Less toxicity, early engraftment and no relapse are the aims of efficient conditioning. Our objective was to investigate the long-term effects of BU-CY and their administration order on the toxicity and chimerism in a mouse model of HSCT. Female BALB/c mice were treated with either BU (15 mg/kg/day x 4)-CY (100 mg/kg/day x 2) or CY-BU. Treated mice were transplanted with Sca-1+ cells from male BALB/c mice. Until 90 days after HSCT, the animals were monitored for body weight and analyzed for cellular phenotype of the thymus, spleen and BM, total chimerism, the spleen chimerism of DCs and T regulatory (Treg) cells, and hepatotoxicity. BU-CY and CY-BU treatments exerted comparable myeloablative and immunosuppressive effects. The long-term engraftment of donor cells in the BM and thymus regeneration showed the same features in both groups. However, the two regimens differed; in general, hepatotoxicity and chimerism of DC and Treg cells. In the long term, BU-CY, but not CY-BU caused a marked decrease in body weight and a significant increase in the activities of the liver enzymes, particularly aspartate amino transferase (AST). We conclude that the alteration of the administration order of BU-CY to CY-BU not only gives the same level of engraftment but also reduces the toxicity of the conditioning regimen that might be valuable specially in young patients who are undergoing HSCT.
Comment in
-
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.Bone Marrow Transplant. 2009 Jun;43(11):883-5. doi: 10.1038/bmt.2008.404. Epub 2008 Dec 15. Bone Marrow Transplant. 2009. PMID: 19079309 Clinical Trial. No abstract available.
Similar articles
-
Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.Exp Hematol. 2005 Mar;33(3):380-7. doi: 10.1016/j.exphem.2004.12.003. Exp Hematol. 2005. PMID: 15730862
-
GVHD after chemotherapy conditioning in allogeneic transplanted mice.Bone Marrow Transplant. 2008 Dec;42(12):807-18. doi: 10.1038/bmt.2008.261. Epub 2008 Sep 29. Bone Marrow Transplant. 2008. PMID: 18820712
-
[Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].Ai Zheng. 2003 Jun;22(6):620-3. Ai Zheng. 2003. PMID: 12948413 Chinese.
-
New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.Semin Oncol. 1993 Aug;20(4 Suppl 4):56-63; quiz 64. Semin Oncol. 1993. PMID: 8342077 Review.
-
The development of busulfan/cyclophosphamide preparative regimens.Semin Oncol. 1993 Aug;20(4 Suppl 4):12-6; quiz 17. Semin Oncol. 1993. PMID: 8342070 Review.
Cited by
-
Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics.Adv Pharmacol Pharm Sci. 2024 Jun 27;2024:4862706. doi: 10.1155/2024/4862706. eCollection 2024. Adv Pharmacol Pharm Sci. 2024. PMID: 38966316 Free PMC article. Review.
-
The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation.Sci Rep. 2018 May 29;8(1):8293. doi: 10.1038/s41598-018-26033-z. Sci Rep. 2018. PMID: 29844459 Free PMC article.
-
Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT).Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):171-176. doi: 10.18502/ijhoscr.v14i3.3725. Int J Hematol Oncol Stem Cell Res. 2020. PMID: 33024523 Free PMC article.
-
Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.Blood Adv. 2022 Aug 9;6(15):4485-4489. doi: 10.1182/bloodadvances.2022007566. Blood Adv. 2022. PMID: 35736667 Free PMC article.
-
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.Ann Hematol. 2021 Jan;100(1):209-216. doi: 10.1007/s00277-020-04312-y. Epub 2020 Oct 23. Ann Hematol. 2021. PMID: 33098041 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials